Welcome to LookChem.com Sign In|Join Free

CAS

  • or

79-57-2

Post Buying Request

79-57-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

79-57-2 Usage

description

Oxytetracycline (PC Code 006304) is a broad-spectrum antibiotic produced from the actinomycete Streptomyces rimosus. Two related compounds, hydroxytetracycline monohydrochloride (PC Code 006308) and oxytetracycline calcium (PC Code 006321), are registered as pesticides, for use in preventing the growth of or killing bacteria, fungi and mycoplasma-like organisms; there is no active product for PC Code 006304. Oxytetracycline is also approved by the Food and Drug Administration (FDA) for use as a human and animal drug to treat a variety of bacterial infections. Specifically, oxytetracycline is used to treat infections caused by chlamydia, mycoplasma organisms, propionebacterium acnes, haemophilus influenzae, and rickettsiae. It acts by inhibiting protein synthesis by binding to the 30S ribosomal subunit of the bacteria. In conjunction with the FDA-approved animal drug uses, food-additive tolerances are established for residues of tetracyclines in commodities of beef cattle, dairy cattle, calves, swine, sheep, chickens, turkeys, finfish, and lobster (21 CFR §556.500).

Physical and Chemical Properties

Isolated from the culture medium of Streptomyces fission; appears as a gray-yellow to yellow crystalline powder. Commonly in a form of hydrochloride; appears as yellow crystal, easily soluble in water, stable under acidic conditions but unstable in alkaline environment. Its oxytetracycline appears as light yellow to dark yellow crystalline powder, insoluble in water. Adjusting the pH to over 8 or below 2 yields oxytetracycline sodium salt or hydrochloride, this is stable and easily soluble in water. The 10% aqueous solution should have a pH of 2.3 to 2.9.

Pharmacology

1. Pharmacodynamics; The drug is a tetracycline antibacterial drug with a broad spectrum of anti-pathogenic microorganisms; appears as a rapid bacteriostatic agent; exhibits bactericidal effect to some bacteria species at high concentration; have a slightly high potency than tetracycline for the treatment of intestinal infections (including amoebic dysentery). Mechanism of action; The drug can specifically bind to the A site of the 30s subunit of the ribosomes in pathogens, preventing the binding of aminoacyl-tRNA to this position, thereby inhibiting the growth of the peptide chain and affecting the protein synthesis of bacteria or other pathogenic microorganisms . Antibacterial spectrum The drug has strong antibacterial activity on Staphylococcus aureus, pneumococcus, Streptococcus pyogenes, Neisseria gonorrhoeae, meningococcal, Escherichia coli, Aerobacter aerogenes, Shigella, Yersinia and Listeria monocytogenes. It also has strong effect on rickettsia, mycoplasma, chlamydia, spirochetes, amoebae and some plasmodium and actinomyces. 2. Pharmacokinetic: oral absorption is not complete (absorb about 30% to 58%); single-dose oral administration of 1 g gives a peak plasma concentration of about 3.9mg / L. The drug is widely distributed after absorption, being capable to penetrate pleural effusion, ascites, can also be distributed in the liver, spleen, bone marrow, bone, dentin and enamel, and can reach a higher concentration in milk. The drug can penetrate through the placental barrier, but not easily through the blood - cerebrospinal fluid barrier. The drug has a distribution volume of 0.9 ~ 1.9L / kg, the protein binding rate of about 20% to 35%, half-life of 6 to 10 hours for people of normal renal function. It has a prolonged half-life for renal failure patients, being as long as 47 to 66 hours for anastomosis patients. The drug is mainly excreted through the glomerular filtration with 70% administered drug being discharged within 24 hours; non-absorbed drugs are excreted in the form of prototype. Hemodialysis can remove about 10% to 15% of the drug.

Adverse reactions

Bone; The medicine can be deposited in the teeth and bones, resulting in varying degrees of discoloration yellow teeth, enamel dysplasia and dental caries, and can cause bone dysplasia. Oral administration of the gastrointestinal tract can cause nausea, vomiting, abdominal discomfort, abdominal distension, diarrhea and other gastrointestinal reactions; occasional esophagitis and esophageal ulcer reported in patients with bed rest immediately after taking medicine. Liver; in rare cases, serum bilirubin, alkaline phosphatase and aminotransferase increase. Long-term medication can cause liver damage, usually leading to hepatic steatosis. People of liver and renal insufficiency, late pregnancy and women receiving high-dose intravenous administration are more likely to suffer. Occasionally also cause both pancreatic inflammation together with liver toxicity. Renal; in rare cases, blood urea nitrogen content increase. Patients with significant renal impairment may have aggravating azotemia, hyperphosphatemia and acidosis. Allergic reaction cases are less than penicillin. It can cause drug fever or rash, the latter can exhibit rash, urticaria, erythema multiforme, eczema-like erythema; can also cause photosensitive dermatitis. In addition, anaphylactic shock, asthma, purpura, etc. are also occasionally reported. Long-term use in blood can cause abnormal lymphocytes, granulocytic granules, hemolytic anemia, thrombocytopenia and neutropenia. Superinfection; Long-term medication can induce drug-resistant Staphylococcus aureus, Gram-negative bacteria and fungi, which lead to the infections in digestive tract, respiratory and urinary tract infections with sepsis occurring in severe cases. Dysbacteriosis; long-term medication can also reduce the body's normal bacteria population, resulting in vitamin deficiency, fungal breeding, dry mouth, sore throat, angular cheilitis, glossitis, dark brown tongue or discoloration. Central nervous system; it has been reported of the cases of benign increased intracranial pressure, manifested as headache, vomiting, optic disc edema and so on.

Drugs interactions

Quinolones: not suitable for combination usage with reduced efficacy and increased side effects. Cephalosporins: oxytetracycline can reduce the antibacterial effect of cephalosporins. Chlortetracycline, kanamycin, olaquindox, enramycin, North rifampin, furinomycin, flavomycin: incompatibility; oxytetracycline are incompatible with the latter combination. Tylosin and other macrolides: combination yields synergistic effect. Polymyxin: combination with oxytetracycline enhances the absorption of the latter, leading to synergistic effect. Penicillins: Antagonistic effect. Metronidazole: combination can reduce the effect of metronidazole, reducing the efficacy. Sodium bicarbonate: increase the pH of oxytetracycline; reduce the dissociation degree and absorption rate. Magnesium sulfate: oxytetracycline can form chelate with magnesium ions; reduce its own absorption and curative effect. TMP: significant synergistic effect. Vitamin C: The latter can inactivate oxytetracycline; oxytetracycline in turn causes faster excretion of vitamin C in the urine. Not suitable. Drugs and feeds containing calcium, magnesium, aluminum and other cationic; prevent the absorption of oxytetracycline and reduce its efficacy. Sodium sulfate: In order to avoid the effect of metal cations in feed; adding appropriate amount of sodium sulfate in the feed can improve the absorption of oxytetracycline and improve the curative effect. Diuretics: Combination can increase blood urea nitrogen, leading to increased renal toxicity. Berberine: combination can enhance antibacterial effect. Vitamin B complex: reduce the effect of oxytetracycline. Bacitracin: incompatibility should not be combined. Food, milk: oxytetracycline, when used with food, milk, the blood concentration is only 20% of that in the cases of fasting drug administration with remarkably compromised antibacterial effect. Trace elements: block the absorption of oxytetracycline, reduce the effect.

Description

Oxytetracycline also is one of the classic tetracyclines. It is produced by fermentation of Streptomyces rimosis and other soil microorganisms. The most hydrophilic tetracycline on the market, it has largely now been replaced by its semisynthetic descendants. It is primarily used today for IM injections.

Chemical Properties

beige to light yellow crystalline powder

Uses

Different sources of media describe the Uses of 79-57-2 differently. You can refer to the following data:
1. Oxytetracycline, which has seen significant usage in plant disease control, does not contain the Cl atom but has an additional -OH group at the C5 position on the tetracycline molecule (4). Tetracyclines are widely used therapeutic agents in clinical medicine [second to penicillins in total tons used each year (5)] for bacterial respiratory, periodontal, and urogenital tract diseases (6). Oxytetracycline is also used as a feed amendment for growth promotion and as a therapeutic agent for curing diseases of agricultural animals including fish.
2. Oxytetracycline(Terramycin) was the second of the broad-spectrum tetracycline group of antibiotics to be discovered. Oxytetracycline works by interfering with the ability of bacteria to produce proteins that are essential to them. Without these proteins t
3. Oxytetracycline (terramycin) is a linear, tetracyclic broad spectrum antibiotic originally isolated from Streptomyces rimosus in 1949. Like all tetracyclines, oxytetracycline shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal sub-units, blocking protein synthesis. Oxytetracycline, although less coloured than other tetracyclines, is still a pigment and is thus sensitive to environmental and storage conditions. Commercial oxytetracycline may contain significant levels of degradation products.

Definition

ChEBI: A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae /ital> (respiratory infections), and Diplococcus pneumoniae.

Therapeutic Function

Antibiotic

Antimicrobial activity

It is slightly less active than other tetracyclines against most common pathogenic bacteria.

Pharmaceutical Applications

A fermentation product of certain strains of Streptomyces rimosus, supplied as the dihydrate or hydrochloride for oral or parenteral administration.

Pharmacokinetics

Oral absorption: c.60% Cmax 500 mg oral: 3–4 mg/L after 2–4 h Plasma half-life: c.9 h Volume of distribution: c.1.8 L/kg Plasma protein binding: 20–35% Oxytetracycline is moderately well absorbed from the upper gastrointestinal tract. Food decreases plasma levels by approximately 50%. Although widely distributed in the tissues, it achieves lower concentrations than related agents such as minocycline. Sputum concentrations of 1 mg/L have been recorded on a daily dosage of 2 g. Approximately 60% is excreted in the urine and the half-life is prolonged in renal insufficiency.

Clinical Use

It offers no unique therapeutic advantages, although it is one of the cheaper preparations.

Side effects

Gastrointestinal intolerance is responsible for most side effects, and tends to be more severe than with other tetracyclines. Esophageal irritation may result from the local effects of the swallowed drug. Potentially serious adverse reactions have included neuromuscular paralysis following intravenous administration to patients with myasthenia gravis. Thrombocytopenic purpura and lupus erythematosus syndrome have been reported, although a direct role for the drug in the latter remains uncertain. Apart from the effect on nitrogen balance common to many tetracyclines, a metabolic effect on glucose homeostasis has been noted in type 1 diabetes mellitus. Allergic contact sensitivity reactions have also been reported.

Synthesis

Oxytetracycline, 4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro- 3,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamide (32.3.2), is synthesized biosynthetically as a result of the activity of actinomycete S. rimosus.

Veterinary Drugs and Treatments

Oxytetracycline products are approved for use in dogs and cats (no known products are being marketed, however), calves, non-lactating dairy cattle, beef cattle, swine, fish, and poultry. For more information, refer to the Doses section, below.

Drug interactions

Potentially hazardous interactions with other drugs Anticoagulants: possibly enhanced anticoagulant effect of coumarins and phenindione. Oestrogens: possibly reduced contraceptive effects of oestrogens (risk probably small). Retinoids: possible increased risk of benign intracranial hypertension with tetracyclines and retinoids - avoid.

Metabolism

Metabolism is negligible. The tetracyclines are excreted in the urine and in the faeces. Renal clearance is by glomerular filtration. Up to 60% of an intravenous dose of tetracycline, and up to 55% of an oral dose, is eliminated unchanged in the urine. The tetracyclines are excreted in the bile, where concentrations 5-25 times those in plasma can occur. There is some enterohepatic reabsorption and considerable quantities occur in the faeces after oral doses.

Toxicity evaluation

Tetracycline is a potent inhibitor of bacterial protein biosynthesis, with less activity on mammalian cells. It binds to the 30S and 50S bacterial ribosomal subunits, and it inhibits the binding of aminoacyl–tRNA and the termination factors RF1 and RF2 to the A site of bacterial ribosomes (21). Acute oral LD50 for mice >7 g/kg; for rats >10 g/kg, acute intravenous 100 ~ 200 mg/kg. Tlm for black bass: 250 ppm (24 h).

Check Digit Verification of cas no

The CAS Registry Mumber 79-57-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 7 and 9 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 79-57:
(4*7)+(3*9)+(2*5)+(1*7)=72
72 % 10 = 2
So 79-57-2 is a valid CAS Registry Number.
InChI:InChI=1/C22H26N2O8/c1-21(31)9-5-4-6-10(25)11(9)17(27)12-13(21)18(28)14-15(24(2)3)16(26)8(20(23)30)7-22(14,32)19(12)29/h4-6,13-15,18,25-26,28-29,31-32H,7H2,1-3H3,(H2,23,30)/t13?,14-,15+,18?,21-,22+/m1/s1

79-57-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name oxytetracycline

1.2 Other means of identification

Product number -
Other names adamycin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only. Veterinary Drug: ANTIMICROBIAL_AGENT
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:79-57-2 SDS

79-57-2Synthetic route

TETRACYCLINE
60-54-8

TETRACYCLINE

A

Oxytetracycline
79-57-2

Oxytetracycline

B

anhydrotetracycline
1665-56-1, 7518-17-4

anhydrotetracycline

Conditions
ConditionsYield
With laccase from Trametes versicolor In water at 25℃; for 24h; pH=6; Catalytic behavior; Kinetics; Reagent/catalyst; pH-value; Enzymatic reaction;
TETRACYCLINE
60-54-8

TETRACYCLINE

Oxytetracycline
79-57-2

Oxytetracycline

Conditions
ConditionsYield
With laccase from Pycnoporus sp. SYBC-L10; 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt In aq. phosphate buffer at 25℃; for 0.0666667h; pH=6; Catalytic behavior; Reagent/catalyst; Temperature; pH-value; Enzymatic reaction;
Oxytetracycline
79-57-2

Oxytetracycline

acetic anhydride
108-24-7

acetic anhydride

(5S,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-8,11-dihydroxy-5-methyl-10,12-dioxo-5,6,6a,7,10,12-hexahydrotetracene-1,5,6,10a(5aH)-tetrayl tetraacetate

(5S,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-8,11-dihydroxy-5-methyl-10,12-dioxo-5,6,6a,7,10,12-hexahydrotetracene-1,5,6,10a(5aH)-tetrayl tetraacetate

Conditions
ConditionsYield
With dmap In dichloromethane at 0 - 25℃; for 1.5h;72%
formaldehyd
50-00-0

formaldehyd

Oxytetracycline
79-57-2

Oxytetracycline

ciprofloxacin
85721-33-1

ciprofloxacin

1-cyclopropyl-7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-piperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

1-cyclopropyl-7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-piperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

Conditions
ConditionsYield
In ethanol for 0.05h; Mannich reaction; microwave irradiation;66%
rhenium(I) pentacarbonyl chloride
14099-01-5

rhenium(I) pentacarbonyl chloride

Oxytetracycline
79-57-2

Oxytetracycline

Re(oxytetracycline)(CO)3Cl

Re(oxytetracycline)(CO)3Cl

Conditions
ConditionsYield
In toluene byproducts: CO; a mixt. in toluene was stirred for about 90 min at 70°C; ppt. was filtered, washed with toluene, pptn. from CH3CN-diethyl ether; elem. anal.;60%
Oxytetracycline
79-57-2

Oxytetracycline

4-dedimethylamino-12a-deoxyterramycin
66762-91-2

4-dedimethylamino-12a-deoxyterramycin

Conditions
ConditionsYield
With zinc In acetic acid at 28℃; for 96h;54%
With acetic acid; zinc
formaldehyd
50-00-0

formaldehyd

Oxytetracycline
79-57-2

Oxytetracycline

1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid
70458-96-7

1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid

7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

Conditions
ConditionsYield
In ethanol for 0.05h; Mannich reaction; microwave irradiation;43%
formaldehyd
50-00-0

formaldehyd

Oxytetracycline
79-57-2

Oxytetracycline

lomefloxacin
98079-51-7

lomefloxacin

7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-3-methyl-piperazin-1-yl)-1-ethyl-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-3-methyl-piperazin-1-yl)-1-ethyl-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

Conditions
ConditionsYield
In ethanol for 0.05h; Mannich reaction; microwave irradiation;41%
formaldehyd
50-00-0

formaldehyd

Oxytetracycline
79-57-2

Oxytetracycline

1-cyclopropyl-7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-3-methyl-piperazin-1-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

1-cyclopropyl-7-(4-{[(4-dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carbonyl)-amino]-methyl}-3-methyl-piperazin-1-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid

Conditions
ConditionsYield
In ethanol for 0.05h; Mannich reaction; microwave irradiation;41%
Oxytetracycline
79-57-2

Oxytetracycline

A

α-apo-oxytetracycline

α-apo-oxytetracycline

B

anhydro-oxytetracycline
4660-26-8

anhydro-oxytetracycline

C

α-apo-oxytetracycline

α-apo-oxytetracycline

D

terrinolide
569-33-5

terrinolide

Conditions
ConditionsYield
With hydrogenchloride In water at 75℃; for 2h;A 23.2%
B n/a
C 7.7%
D 33.1%
Oxytetracycline
79-57-2

Oxytetracycline

A

tertamethylammonium iodide
75-58-1

tertamethylammonium iodide

B

2,3,6-trihydroxybenzamide
101495-28-7

2,3,6-trihydroxybenzamide

C

(1S,9R,12S)-6-Hydroxy-1-methyl-8,10-dioxo-11-oxa-tricyclo[7.2.1.02,7]dodeca-2(7),3,5-triene-12-carbaldehyde
78796-73-3

(1S,9R,12S)-6-Hydroxy-1-methyl-8,10-dioxo-11-oxa-tricyclo[7.2.1.02,7]dodeca-2(7),3,5-triene-12-carbaldehyde

D

terramycin hydroiodide
78796-72-2

terramycin hydroiodide

Conditions
ConditionsYield
With methyl iodide In acetone for 336h; Ambient temperature;A n/a
B n/a
C 12.7%
D n/a
Oxytetracycline
79-57-2

Oxytetracycline

methyl iodide
74-88-4

methyl iodide

A

tertamethylammonium iodide
75-58-1

tertamethylammonium iodide

B

2,3,6-trihydroxybenzamide
101495-28-7

2,3,6-trihydroxybenzamide

C

(1S,9R,12S)-6-Hydroxy-1-methyl-8,10-dioxo-11-oxa-tricyclo[7.2.1.02,7]dodeca-2(7),3,5-triene-12-carbaldehyde
78796-73-3

(1S,9R,12S)-6-Hydroxy-1-methyl-8,10-dioxo-11-oxa-tricyclo[7.2.1.02,7]dodeca-2(7),3,5-triene-12-carbaldehyde

D

terramycin hydroiodide
78796-72-2

terramycin hydroiodide

Conditions
ConditionsYield
In acetone for 336h; Ambient temperature;A n/a
B n/a
C 12.7%
D n/a
Oxytetracycline
79-57-2

Oxytetracycline

(4aR)-3,5c,6t,10,12,12a-hexahydroxy-6c-methyl-1,11-dioxo-(4ar,5ac,12ac)-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
4495-20-9

(4aR)-3,5c,6t,10,12,12a-hexahydroxy-6c-methyl-1,11-dioxo-(4ar,5ac,12ac)-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide

Conditions
ConditionsYield
With acetic acid; zinc
Oxytetracycline
79-57-2

Oxytetracycline

4-epi-oxytetracycline
14206-58-7

4-epi-oxytetracycline

Conditions
ConditionsYield
With acetic acid
2-amino-1,9-dihydro-6H-purin-6-one
73-40-5

2-amino-1,9-dihydro-6H-purin-6-one

Oxytetracycline
79-57-2

Oxytetracycline

guanine*oxytetracycline
78696-84-1

guanine*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
L-phenylalanine
63-91-2

L-phenylalanine

Oxytetracycline
79-57-2

Oxytetracycline

phenylalanine*oxytetracycline
78696-88-5

phenylalanine*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

L-tyrosine
60-18-4

L-tyrosine

tyrosine*oxytetracycline
78696-89-6

tyrosine*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

uracil
66-22-8

uracil

uracil*oxytetracycline
78696-87-4

uracil*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

thymin
65-71-4

thymin

thymine*oxytetracycline
78714-53-1

thymine*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

hypoxanthine
68-94-0

hypoxanthine

hypoxanthine*oxytetracycline
78696-86-3

hypoxanthine*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

xanthine
69-89-6

xanthine

xanthine*oxytetracycline
78696-85-2

xanthine*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

5-sulfosalicylic Acid
97-05-2

5-sulfosalicylic Acid

oxytetracycline 5-sulphosalicylate
61068-97-1

oxytetracycline 5-sulphosalicylate

Conditions
ConditionsYield
In water pH 2;
Oxytetracycline
79-57-2

Oxytetracycline

L-histidine
71-00-1

L-histidine

histidine*oxytetracycline
78696-90-9

histidine*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

L-Tryptophan
73-22-3

L-Tryptophan

tryptophan*oxytetracycline
78696-91-0

tryptophan*oxytetracycline

Conditions
ConditionsYield
In water at 23℃; formation constant; further solvents;;
Oxytetracycline
79-57-2

Oxytetracycline

acetic acid
64-19-7

acetic acid

5-hydroxy-4-epi-tetracycline

5-hydroxy-4-epi-tetracycline

methanol
67-56-1

methanol

Oxytetracycline
79-57-2

Oxytetracycline

palladium/charcoal

palladium/charcoal

5-hydroxy-6-deoxy-6-epi-tetracycline

5-hydroxy-6-deoxy-6-epi-tetracycline

Conditions
ConditionsYield
Hydrogenation;
hydrogenchloride
7647-01-0

hydrogenchloride

Oxytetracycline
79-57-2

Oxytetracycline

acetone
67-64-1

acetone

N-<α-hydroxy-isopropyl>-derivative of anhydroterramycin

N-<α-hydroxy-isopropyl>-derivative of anhydroterramycin

hydrogenchloride
7647-01-0

hydrogenchloride

Oxytetracycline
79-57-2

Oxytetracycline

(3S)-4t-[(R)-4,5-dihydroxy-9-methyl-3-oxo-1,3-dihydro-naphtho[2,3-c]furan-1-yl)-3r-dimethylamino-2,5ξ-dihydroxy-6-oxo-cyclohex-1-enecarboxylic acid amide
2869-27-4, 18695-01-7, 18751-99-0

(3S)-4t-[(R)-4,5-dihydroxy-9-methyl-3-oxo-1,3-dihydro-naphtho[2,3-c]furan-1-yl)-3r-dimethylamino-2,5ξ-dihydroxy-6-oxo-cyclohex-1-enecarboxylic acid amide

hydrogenchloride
7647-01-0

hydrogenchloride

Oxytetracycline
79-57-2

Oxytetracycline

air

air

A

(3S)-4t-[(R)-4,5-dihydroxy-9-methyl-3-oxo-1,3-dihydro-naphtho[2,3-c]furan-1-yl)-3r-dimethylamino-2,5ξ-dihydroxy-6-oxo-cyclohex-1-enecarboxylic acid amide
2869-27-4, 18695-01-7, 18751-99-0

(3S)-4t-[(R)-4,5-dihydroxy-9-methyl-3-oxo-1,3-dihydro-naphtho[2,3-c]furan-1-yl)-3r-dimethylamino-2,5ξ-dihydroxy-6-oxo-cyclohex-1-enecarboxylic acid amide

B

terrinolide
569-33-5

terrinolide

79-57-2Upstream product

79-57-2Relevant articles and documents

Characterization of a robust cold-adapted and thermostable laccase from Pycnoporus sp. SYBC-L10 with a strong ability for the degradation of tetracycline and oxytetracycline by laccase-mediated oxidation

Tian, Qiaopeng,Dou, Xin,Huang, Lin,Wang, Lei,Meng, Di,Zhai, Lixin,Shen, Yu,You, Cuiping,Guan, Zhengbing,Liao, Xiangru

, (2020)

A native laccase (Lac-Q) with robust cold-adapted and thermostable characteristics from the white-rot fungus Pycnoporus sp. SYBC-L10 was purified, characterized, and used in antibiotic treatments. Degradation experiments revealed that Lac-Q at 10.0 U mL?1 coupled with 1.0 mmol L?1 ABTS could degrade 100% of the tetracycline or oxytetracycline (50 mg L?1) within 5 min with a static incubation at 0 °C (pH 6.0). The presence of the Mn2+ ion inhibited the removal rate of tetracycline and oxytetracycline by the Lac-Q–ABTS system, and the presence of Al3+, Cu2+, and Fe3+ accelerated the removal rate of tetracycline and oxytetracycline by the Lac-Q–ABTS system. Furthermore, seven transformation products of oxytetracycline (namely TP 445, TP 431, TP 413, TP 399, TP 381, TP 367, and TP 351) were identified during the Lac-Q-mediated oxidation process by using UPLC–MS/MS. A possible degradation pathway including deamination, demethylation, and dehydration was proposed. Furthermore, the growth inhibition of Bacillus altitudinis SYBC hb4 and E. coli by tetracycline antibiotics revealed that the antimicrobial activity was significantly reduced after treatment with the Lac-Q–ABTS system. Finally, seven transformation products of oxytetracycline (namely TP 445, TP 431, TP 413, TP 399, TP 381, TP 367, and TP 351) were identified during the Lac-Q-mediated oxidation process by using UPLC–MS/MS. A possible degradation pathway including deamination, demethylation, and dehydration was proposed. These results suggest that the Lac-Q–ABTS system shows a great potential for the treatment of antibiotic wastewater containing different metal ions at various temperatures.

Compositions and methods for treating hemorrhagic virus infections and other disorders

-

, (2008/06/13)

Cytokine-receptor and cytokine antagonist-enriched blood-dervided compositions and methods of preparing and using the compositions are provided. Also provided are compositions and methods for the treatment or prevention of disorders, especially acute inflammatory disorders involving pathological responses of the immune system, such as viral hemorrhagic diseases, sepsis, rheumatoid arthritis and other autoimmune disorders, acute cardiovascular events, flare-ups and acute phases of multiple sclerosis, wasting disorders and other disorders involving deleterious expression of cytokines and other factors, including tumor necrosis factor (TNF) and interleukin-1 (IL-1) are provided.

Drug releasing surgical implant or dressing material

-

, (2008/06/13)

A surgical implant or external wound dressing which functions as both a hemostat and a device to safely and effectively deliver any of a number of pharmaceuticals to targeted tissue at a controlled rate is disclosed. The device generally comprises a carrier in the form of fibers, sutures, fabrics, cross-linked solid foams or bandages, a pharmaceutical in solid micoparticulate form releasably bound to the carrier fibers, and a lipid adjuvant which aids the binding of the microparticles to the fibers as well as their function in the body.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 79-57-2